Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)
Inventors
Narain, Niven Rajin • McCook, John Patrick
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11028446-B2
Publication Date
2021-06-08
Expiration Date
Abstract
Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described.
Core Innovation
The invention relates to a method for treating an oncological disorder in a human by administering Coenzyme Q10 (CoQ10) in its oxidized form. The CoQ10 has a purity between 95% and 100%, and administration results in an increase of CoQ10 in the oxidized form in the human.
The oncological disorder is selected from pancreatic carcinoma, hepatocellular carcinoma, Ewing's sarcoma, breast cancer, brain cancer, astrocytoma, neuroendocrine cancer, colon cancer, lung cancer, osteosarcoma, prostate cancer, ovarian cancer, Squamous cell Carcinoma, Basal Cell Carcinoma and non-Hodgkin's Lymphoma.
The document describes CoQ10 as a multidimensional intracellular molecule and an Epi-shifter, with cancer-associated apoptosis and mitochondrial localization or enrichment. It also reports modulation of cancer-cell metabolism and apoptotic pathways, including effects on cancer growth, glycolysis, metabolism, transport, signaling, and bioenergetic shifts.
Claims Coverage
The claim coverage identifies one independent claim directed to treating an oncological disorder by administering oxidized CoQ10 with specified purity and an increase of oxidized CoQ10 in the human. Dependent claims add refinements including apoptosis or cell death, intravenous administration, concurrent administration with an additional therapeutic agent, a minimum dosing threshold, and cancer-type restrictions.
Oxidized CoQ10 administration for treating an oncological disorder
Administering Coenzyme Q10 (CoQ10) to the human such that treatment occurs, wherein the CoQ10 is in its oxidized form and has a purity between 95% and 100%, and wherein administration results in an increase of CoQ10 in the oxidized form in the human.
Oncological disorder selection for treatment
The oncological disorder is selected from pancreatic carcinoma, hepatocellular carcinoma, Ewing's sarcoma, breast cancer, brain cancer, astrocytoma, neuroendocrine cancer, colon cancer, lung cancer, osteosarcoma, prostate cancer, ovarian cancer, Squamous cell Carcinoma, Basal Cell Carcinoma and non-Hodgkin's Lymphoma.
Inducing apoptosis or cell death
Administration of CoQ10 to induce apoptosis or cell death in a cancerous cell of an oncological disorder.
Administration route specification
Administering Coenzyme Q10 intravenously.
Concurrent administration with an additional therapeutic agent
Administering Coenzyme Q10 concurrently with an additional therapeutic agent.
Quantitative minimum dosing threshold
Administering Coenzyme Q10 at a dose of at least 5 mg/kg.
The claims center on administering oxidized CoQ10 of specified purity so that oxidized CoQ10 increases in the human to treat a listed oncological disorder, with additional features for apoptosis or cell death, intravenous administration, concurrent combination therapy, and a minimum dosing threshold.
Stated Advantages
Selective apoptosis and cell death in cancer cells versus normal cells.
Increased sensitivity of aggressive cancer cell lines.
Maintenance of mitochondrial accumulation of CoQ10 primarily in the oxidized, pro-oxidant form.
Modulation of multiple gene and protein pathways, including apoptosis, cancer growth, glycolysis/metabolism, transport, and signaling.
Improved survival in the in vivo pancreatic cancer study with IV CoQ10.
Mitigated doxorubicin toxicity in the in vivo pancreatic cancer study.
Increased caspase-3 and altered apoptotic-related proteins associated with apoptotic pathways.
Documented Applications
Treatment of oncological disorders in a human, including pancreatic carcinoma, hepatocellular carcinoma, Ewing's sarcoma, breast cancer, brain cancer, astrocytoma, neuroendocrine cancer, colon cancer, lung cancer, osteosarcoma, prostate cancer, ovarian cancer, Squamous cell Carcinoma, Basal Cell Carcinoma and non-Hodgkin's Lymphoma.
Pancreatic cancer application, including an in vivo pancreatic cancer study where IV CoQ10 improved survival and mitigated doxorubicin toxicity.
Cell-line studies identifying CoQ10 as a multidimensional intracellular molecule using oxidized CoQ10.
Interested in licensing this patent?